CN110996993B - 包含源自超抗原类毒素的融合肽的免疫原性组合物 - Google Patents

包含源自超抗原类毒素的融合肽的免疫原性组合物 Download PDF

Info

Publication number
CN110996993B
CN110996993B CN201880047111.4A CN201880047111A CN110996993B CN 110996993 B CN110996993 B CN 110996993B CN 201880047111 A CN201880047111 A CN 201880047111A CN 110996993 B CN110996993 B CN 110996993B
Authority
CN
China
Prior art keywords
lys
toxoid
oligopeptide
leu
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880047111.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN110996993A (zh
Inventor
穆罕默德·贾瓦德·阿曼
托马斯·科尔特
阿伦达提·文卡塔苏布拉曼尼亚
尼尔斯·威利斯顿
拉詹·普拉萨德·阿迪卡里
弗雷德里克·W·霍尔茨伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaccine Co AB
Integrated Biotherapeutic Vaccines Inc
Original Assignee
Vaccine Co AB
Integrated Biotherapeutic Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccine Co AB, Integrated Biotherapeutic Vaccines Inc filed Critical Vaccine Co AB
Publication of CN110996993A publication Critical patent/CN110996993A/zh
Application granted granted Critical
Publication of CN110996993B publication Critical patent/CN110996993B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880047111.4A 2017-07-27 2018-07-25 包含源自超抗原类毒素的融合肽的免疫原性组合物 Active CN110996993B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762537706P 2017-07-27 2017-07-27
US62/537,706 2017-07-27
PCT/US2018/043687 WO2019023341A1 (en) 2017-07-27 2018-07-25 IMMUNOGENIC COMPOSITION COMPRISING A MELTING PEPTIDE DERIVED FROM TOXOIDS OF SUPERANTIGENES

Publications (2)

Publication Number Publication Date
CN110996993A CN110996993A (zh) 2020-04-10
CN110996993B true CN110996993B (zh) 2024-05-31

Family

ID=65041106

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880047111.4A Active CN110996993B (zh) 2017-07-27 2018-07-25 包含源自超抗原类毒素的融合肽的免疫原性组合物

Country Status (7)

Country Link
US (2) US11260120B2 (enExample)
EP (1) EP3658181A4 (enExample)
JP (1) JP7303791B2 (enExample)
CN (1) CN110996993B (enExample)
CA (1) CA3069747A1 (enExample)
MX (1) MX2020001046A (enExample)
WO (1) WO2019023341A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116497003B (zh) * 2023-06-29 2026-07-14 北京百普赛斯生物科技股份有限公司 一种从溶液中纯化目标蛋白的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593114B1 (en) 1996-01-05 2003-07-15 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US6713284B2 (en) 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
US7087235B2 (en) 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
AU761021B2 (en) 1998-07-10 2003-05-29 U.S. Medical Research Institute Of Infectious Diseases Department Of The Army Vaccine against staphylococcus intoxication
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0118155D0 (en) 2001-07-25 2001-09-19 Lorantis Ltd Superantigen
AU2002227232A1 (en) 2001-11-26 2003-07-15 U.S. Medical Research Institute Of Infectious Diseases Bacterial superantigen vaccines
NZ561879A (en) 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US7754225B2 (en) 2006-07-20 2010-07-13 Glaxosmithkline Biologicals S.A. Method of protecting against staphylococcal infection
WO2008154101A1 (en) 2007-06-06 2008-12-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Psm peptides as vaccine targets against methicillin-resistant staphylococcus aureus
KR20100072228A (ko) 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
AU2012214677B2 (en) 2011-02-08 2016-11-10 Abvacc, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
CN103561762A (zh) 2011-03-16 2014-02-05 明尼苏达大学董事会 诱导针对葡萄球菌属中细菌的免疫应答的组合物和方法
CA2857666C (en) 2011-12-02 2020-08-11 Integrated Biotherapeutics, Inc. Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
CA2916231C (en) 2013-06-19 2024-02-06 Integrated Biotherapeutics, Inc. Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Characterization of two distinct MHC class 11 binding sites in the superantigen staphylococcal enterotoxin A;Lars Abrahmsen等;《The EMBO Journal》;第14卷(第13期);第2978-2986页 *
Structural basis for abrogated binding between staphylococcal enterotoxin A superantigen vaccine and MHC-IIα;HEIKE I. KRUPKA等;《Protein Science》;第11卷(第3期);第642-651页 *

Also Published As

Publication number Publication date
US11826412B2 (en) 2023-11-28
EP3658181A4 (en) 2021-06-16
WO2019023341A1 (en) 2019-01-31
US11260120B2 (en) 2022-03-01
JP2020537488A (ja) 2020-12-24
JP7303791B2 (ja) 2023-07-05
EP3658181A1 (en) 2020-06-03
US20200206335A1 (en) 2020-07-02
US20220257744A1 (en) 2022-08-18
MX2020001046A (es) 2020-08-06
CA3069747A1 (en) 2019-01-31
CN110996993A (zh) 2020-04-10

Similar Documents

Publication Publication Date Title
US10174085B2 (en) Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
AU2012214677B2 (en) Immunogenic composition comprising alpha-hemolysin oligopeptides
EP2785368B1 (en) Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
US11421021B2 (en) Immunogenic compositions comprising Staphylococcus aureus leukocidin LukA and LukB derived polypeptides
US11826412B2 (en) Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
US20180141981A1 (en) Immunogenic composition comprising engineered alpha-hemolysin oligopeptides
GR1010289B (el) Τοξοειδη πεπτιδια που προερχονται απο διαλυτη σε φαινολη μοδουλινη, τοξινη δελτα, υπεραντιγονα και συντηξεις αυτων
CA3066450C (en) Immunogenic compositions comprising staphylococcus aureus leukocidin luka and lukb derived polypeptides
NZ626762B2 (en) Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information
CB02 Change of applicant information

Address after: American Maryland

Applicant after: Integrated biotherapy vaccine Co.

Address before: Delaware, USA

Applicant before: Integrated biotherapy vaccine Co.

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Maryland, USA

Applicant after: AB Vaccine Co.

Address before: Maryland, USA

Applicant before: Integrated biotherapy vaccine Co.

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20381009

TG01 Patent term adjustment